MetLife (MET)
(Delayed Data from NYSE)
$72.72 USD
+0.50 (0.69%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $72.74 +0.02 (0.03%) 7:34 PM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
MetLife (MET) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$84.33 | $104.00 | $71.00 | 16.77% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for MetLife comes to $84.33. The forecasts range from a low of $71.00 to a high of $104.00. The average price target represents an increase of 16.77% from the last closing price of $72.22.
Analyst Price Targets (12)
Broker Rating
MetLife currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, 10 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 13.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 13.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 11 | 11 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.47 | 1.47 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | Keefe Bruyette & Woods | Ryan Krueger | Moderate Buy | Moderate Buy |
4/5/2024 | Piper Sandler | John Barnidge | Strong Buy | Strong Buy |
3/12/2024 | Not Identified | Not Identified | Hold | Hold |
2/1/2024 | Evercore Partners | Thomas Gallagher | Strong Buy | Strong Buy |
1/16/2024 | Dowling & Partners | Joel Hurwitz | Not Available | Hold |
8/14/2023 | Argus Research Corp. | Kevin M Heal | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 15 |
Average Target Price | $84.33 |
LT Growth Rate | 15.30% |
Industry | Insurance - Multi line |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | 1.83 |